Hemoglobin Fluctuations and Correlation with Quality of Life and Fatigue

  • G. Caocci
  • R. Baccoli
  • G. La Nasa
Reference work entry


A reduction of  Hemoglobin (Hb) levels is common in patients with hematologic malignancies such as  Multiple Myeloma (MM) and  Myelodysplastic syndromes (MDS) and is a frequent complication of myelosuppressive chemotherapy.  Anemia is often associated with a severe impact on physical well-being, quality of life (QOL) and fatigue. Treatment of anemia requires red blood cell (RBC) transfusions, but in a high proportion of patients it is possible to achieve sustained levels of Hb with  recombinant human erythropoietin (rHuEPO and Darbepoetin alfa). Although Hb levels are routinely used to assess the severity of anemia, this numeric gradient does not clearly correlate with the clinical symptoms of anemia, which may be different among patients with the same Hb levels. Hematologic patients under poly-transfusion or treated with erythropoietin-stimulating agents may experience recurrent Hb fluctuations. Repeated RBC transfusions are associated with highly variable and unstable Hb concentrations and the fluctuating Hb may negatively influence homeostasis. Dynamic Hb fluctuations may increase fatigue and ulteriorly aggravate QOL due to recurrent “down-up-down” Hb excursions. These considerations prompted a group of researchers to create a mathematical model capable of transforming measurements of Hb fluctuations into a numerical parameter (  Variaglobin Index) and to correlate this parameter with quality of life and fatigue. Among transfusion-dependent MDS patients and transfusion-free MDS and MM patients (MDS patients treated with rHuEPO and MM patients treated with derbepoietin alfa), a lower amplitude of the Variaglobin Index was found to be significantly correlated with a better quality of life and less fatigue. No significant differences were observed for the amplitude of Hb fluctuations when comparing patients treated with Darbepoetin alfa or rHuEPO.

This innovative mathematical model makes it easy to monitor anemia in oncohematologic patients and to adjust therapy accordingly.


Multiple Myeloma Darbepoetin Alfa Recombinant Human Erythropoietin International Prognostic Scoring System Hematologic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


European Organization for Research and Treatment Of Cancer






 International Prognostic Scoring System


myelodysplastic syndromes


multiple myeloma


quality of life questionnaire with 30 items


quality of life


red blood cell


recombinant human erythropoietin


  1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ. (1993). J Natl Cancer Inst. 85: 365–376.PubMedCrossRefGoogle Scholar
  2. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, Locatelli F, Marchetti M, Morra E, Rebulla P, Visani G, Tura S. (2002). Haematologica. 87: 1286–1306.PubMedGoogle Scholar
  3. Andersson RT, Aaronson NK, Willen D. (1993). Qual Life 2: 369–395.CrossRefGoogle Scholar
  4. Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, Merlini G, Tosi P, Tura S. (2004). Haematologica. 89: 717–741.PubMedGoogle Scholar
  5. Bennett JM. (2000). Int J Hematol. 72: 131–133.PubMedGoogle Scholar
  6. Berns JS, Fishbane S. (2005). Semin Dial. 19: 257–259.CrossRefGoogle Scholar
  7. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P. (2007). Eur J Cancer. 43: 258–270.PubMedCrossRefGoogle Scholar
  8. Caocci G, Baccoli R, Ledda A, Littera R, La Nasa G. (2007). Leuk Res. 31: 249–252.PubMedCrossRefGoogle Scholar
  9. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarrè MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P. (2004). Blood. 104: 321–327.PubMedCrossRefGoogle Scholar
  10. Cazzola M, Malcovati.(2005). N Engl J Med. 352: 536–538.PubMedCrossRefGoogle Scholar
  11. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus M. (2005). Am J Kidney Dis. 46: 481–488.PubMedCrossRefGoogle Scholar
  12. Fishbane S, Berns JS. (2005). Kidney Int. 68: 1337–1343.PubMedCrossRefGoogle Scholar
  13. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. (2007). Blood. 89: 2079–2088.Google Scholar
  14. Groopman JE, Itri JE. (2000). J Natl Cancer Inst. 91: 1616–1634.Google Scholar
  15. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altés A, Martinella G, Watson D, Matcham J, Rossi G, Littlewood TJ. (2003). Br J Haematol. 122: 394–403.PubMedCrossRefGoogle Scholar
  16. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Alghren T, Dahl IM, Dyberal I, Grimfors G, Hesse-Sundin E, Hjorton M, Kanter-Lewenshon L, Linder O, Luthman M, Löfvenberg E, Öberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F. (2005). Br J Haematol. 29: 1217–1219.Google Scholar
  17. Jamal NM, Kryzanski W, Cheung W, Lau CY, Messner HA. (2006). J Int Med Res. 34: 42–51.PubMedGoogle Scholar
  18. Jansen AJG, Essink-Bot ML, Beckers EAM, Hop WCJ, Schippeurus MR, Van Rhenen DJ. (2003). Br J Haematol. 121: 270–274.PubMedCrossRefGoogle Scholar
  19. Khayat D. (2000). Semin Oncol. 27 (Suppl 4): 9–11.PubMedGoogle Scholar
  20. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. (2003). Mayo Clin Proc. 78: 21–33.PubMedCrossRefGoogle Scholar
  21. Ludwig H, Fritz E, Leitgeb C. (1993). Ann Oncol. 4: 161–167.PubMedGoogle Scholar
  22. Oliva EN, Dimitrov BD, Benedetto F, D’Angelo A, Nobile F. (2005). Leuk Res. 29: 1217–1219.PubMedCrossRefGoogle Scholar
  23. Österborg A. (2002). In: Nowrousian (ed.) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology – Scientific and Clinical Aspects of Anemia in Cancer – Part 2. Springer-Verlag, Wien New York, pp. 224.Google Scholar
  24. Richardson A. (1995). Eur J Cancer Care. 4: 20–32.CrossRefGoogle Scholar
  25. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennet CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. (2002). J Clin Oncol. 20: 4083–4107.PubMedCrossRefGoogle Scholar
  26. Sardell AN, Trierweiler SJ. (1997). Cancer. 72: 3355–3365.CrossRefGoogle Scholar
  27. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ. (2004). Leukemia. 18: 809–816.PubMedCrossRefGoogle Scholar
  28. Servaes P, Verhagen C, Bleijenberg G. (2002). Eur J Cancer. 38: 27–43.PubMedCrossRefGoogle Scholar
  29. Thomas ML. (1998). Leuk Res. 22:s41–s47.PubMedCrossRefGoogle Scholar
  30. Walker R, Pussel BA. (2007) Nephrology 12: 448–451.PubMedCrossRefGoogle Scholar
  31. Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J. (1996). Br J Haematol. 92: 604–613.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • G. Caocci
  • R. Baccoli
  • G. La Nasa

There are no affiliations available

Personalised recommendations